• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma.

作者信息

Hu G, Dasari S, Asmann Y W, Greipp P T, Knudson R A, Benson H K, Li Y, Eckloff B W, Jen J, Link B K, Jiang L, Sidhu J S, Wellik L E, Witzig T E, Bennani N N, Cerhan J R, Boddicker R L, Feldman A L

机构信息

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

出版信息

Leukemia. 2018 Feb;32(2):565-569. doi: 10.1038/leu.2017.309. Epub 2017 Oct 13.

DOI:10.1038/leu.2017.309
PMID:29026208
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5803446/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82dc/5803446/46067a312661/nihms911575f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82dc/5803446/c3224414c5b4/nihms911575f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82dc/5803446/46067a312661/nihms911575f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82dc/5803446/c3224414c5b4/nihms911575f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82dc/5803446/46067a312661/nihms911575f2.jpg

相似文献

1
Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma.ALK阴性间变性大细胞淋巴瘤中FRK酪氨酸激酶的可靶向融合
Leukemia. 2018 Feb;32(2):565-569. doi: 10.1038/leu.2017.309. Epub 2017 Oct 13.
2
[Expression of anaplastic lymphoma kinase and survivin proteins in anaplastic large cell lymphoma and its significance].间变性大细胞淋巴瘤中间变性淋巴瘤激酶和生存素蛋白的表达及其意义
Zhonghua Bing Li Xue Za Zhi. 2006 Apr;35(4):213-7.
3
Novel ALK fusion in anaplastic large cell lymphoma involving EEF1G, a subunit of the eukaryotic elongation factor-1 complex.间变性大细胞淋巴瘤中涉及真核延伸因子-1复合物亚基EEF1G的新型ALK融合。
Leukemia. 2017 Mar;31(3):743-747. doi: 10.1038/leu.2016.331. Epub 2016 Nov 14.
4
[Study on activation of AKT/mTOR pathway in anaplastic large cell lymphoma].间变性大细胞淋巴瘤中AKT/mTOR通路激活的研究
Zhonghua Xue Ye Xue Za Zhi. 2008 Oct;29(10):649-53.
5
The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.致癌的 JUNB/CD30 轴促进 ALK+间变大细胞淋巴瘤中的细胞周期失调。
Br J Haematol. 2014 Nov;167(4):514-23. doi: 10.1111/bjh.13079. Epub 2014 Aug 22.
6
[Clinicopathologic features of 66 cases of anaplastic lymphoma kinase positive and negative systemic anaplastic large cell lymphoma: a comparative study].66例间变性淋巴瘤激酶阳性与阴性系统性间变性大细胞淋巴瘤的临床病理特征：一项对比研究
Zhonghua Bing Li Xue Za Zhi. 2010 Apr;39(4):235-9.
7
Correlation of seven biological factors (Hsp90a, p53, MDM2, Bcl-2, Bax, Cytochrome C, and Cleaved caspase3) with clinical outcomes of ALK+ anaplastic large-cell lymphoma.七种生物因子（Hsp90a、p53、MDM2、Bcl-2、Bax、细胞色素 C 和Cleaved caspase3）与ALK+间变大细胞淋巴瘤临床结局的相关性。
Biomed Environ Sci. 2011 Dec;24(6):630-41. doi: 10.3967/0895-3988.2011.06.007.
8
Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas.间变性淋巴瘤激酶阳性和间变性淋巴瘤激酶阴性间变性大细胞淋巴瘤中的差异基因表达
Hum Pathol. 2005 May;36(5):494-504. doi: 10.1016/j.humpath.2005.03.004.
9
Involvement of oncogenic tyrosine kinase NPM-ALK in trifluoperazine-induced cell cycle arrest and apoptosis in ALK anaplastic large cell lymphoma.致癌性酪氨酸激酶NPM-ALK参与三氟拉嗪诱导的ALK间变性大细胞淋巴瘤细胞周期阻滞和凋亡。
Hematology. 2018 Jun;23(5):284-290. doi: 10.1080/10245332.2017.1396045. Epub 2017 Oct 31.
10
Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.间变性淋巴瘤激酶阳性间变性大细胞淋巴瘤：成人和儿童疾病的现状与未来展望
Eur J Haematol. 2014 Dec;93(6):455-68. doi: 10.1111/ejh.12360. Epub 2014 May 21.

引用本文的文献

1
Molecular Insights into the Diagnosis of Anaplastic Large Cell Lymphoma: Beyond Morphology and Immunophenotype.间变性大细胞淋巴瘤诊断的分子见解：超越形态学和免疫表型
Int J Mol Sci. 2025 Jun 19;26(12):5871. doi: 10.3390/ijms26125871.
2
Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions.结外周 T 细胞淋巴瘤的病理生物学：当前认识与未来方向。
Haematologica. 2023 Dec 1;108(12):3227-3243. doi: 10.3324/haematol.2023.282716.
3
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders.

本文引用的文献

1
TrkA is a binding partner of NPM-ALK that promotes the survival of ALK T-cell lymphoma.TrkA 是 NPM-ALK 的结合伴侣，可促进 ALK T 细胞淋巴瘤的存活。
Mol Oncol. 2017 Sep;11(9):1189-1207. doi: 10.1002/1878-0261.12088. Epub 2017 Jun 18.
2
Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology.了解Fyn相关激酶（FRK）的细胞作用：对癌症生物学的启示。
Cancer Metastasis Rev. 2016 Jun;35(2):179-99. doi: 10.1007/s10555-016-9623-3.
3
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
T 细胞淋巴瘤和淋巴组织增生性疾病分类的更新。
Curr Hematol Malig Rep. 2023 Dec;18(6):252-263. doi: 10.1007/s11899-023-00712-9. Epub 2023 Oct 23.
4
Leukaemic cells expressing ETV6::FRK are sensitive to dasatinib in vivo.表达ETV6::FRK的白血病细胞在体内对达沙替尼敏感。
EJHaem. 2023 May 2;4(3):751-755. doi: 10.1002/jha2.701. eCollection 2023 Aug.
5
How molecular advances may improve the diagnosis and management of PTCL patients.分子学进展如何改善外周T细胞淋巴瘤（PTCL）患者的诊断与管理。
Front Oncol. 2023 Jun 23;13:1202964. doi: 10.3389/fonc.2023.1202964. eCollection 2023.
6
Mature T-cell and NK-cell lymphomas: updates on molecular genetic features.成熟T细胞和NK细胞淋巴瘤：分子遗传学特征的最新进展
Int J Hematol. 2023 Apr;117(4):475-491. doi: 10.1007/s12185-023-03537-7. Epub 2023 Jan 13.
7
Genomic profiling for clinical decision making in lymphoid neoplasms.淋巴肿瘤临床决策的基因组分析。
Blood. 2022 Nov 24;140(21):2193-2227. doi: 10.1182/blood.2022015854.
8
Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma.原发性皮肤间变大细胞淋巴瘤的全基因组分析。
Haematologica. 2022 Jul 1;107(7):1619-1632. doi: 10.3324/haematol.2020.263251.
9
TRIM44 promotes cell proliferation and migration by inhibiting FRK in renal cell carcinoma.TRIM44 通过抑制肾细胞癌中的 FRK 促进细胞增殖和迁移。
Cancer Sci. 2020 Mar;111(3):881-890. doi: 10.1111/cas.14295. Epub 2020 Jan 20.
10
Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.T 细胞淋巴瘤、霍奇金淋巴瘤和组织细胞/树突状细胞肿瘤分类的更新。
Expert Rev Hematol. 2019 Oct;12(10):833-843. doi: 10.1080/17474086.2019.1647777. Epub 2019 Jul 31.
《世界卫生组织淋巴组织肿瘤分类（2016年修订版）》
Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15.
4
Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts.鉴定表达异常水平 ERBB4 转录本的新型 ALK 阴性 ALCL 亚类。
Blood. 2016 Jan 14;127(2):221-32. doi: 10.1182/blood-2014-12-614503. Epub 2015 Oct 13.
5
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.趋同突变和激酶融合导致间变性大细胞淋巴瘤中致癌性STAT3激活。
Cancer Cell. 2015 Apr 13;27(4):516-32. doi: 10.1016/j.ccell.2015.03.006.
6
Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous.间变性大细胞淋巴瘤：ALK阳性、ALK阴性及原发性皮肤型。
Adv Anat Pathol. 2015 Jan;22(1):29-49. doi: 10.1097/PAP.0000000000000047.
7
A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders.一种新的 NPM1-TYK2 基因融合在皮肤 CD30 阳性淋巴增生性疾病中的发现。
Blood. 2014 Dec 11;124(25):3768-71. doi: 10.1182/blood-2014-07-588434. Epub 2014 Oct 27.
8
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.ALK阴性间变性大细胞淋巴瘤是一种基因异质性疾病，临床结局差异很大。
Blood. 2014 Aug 28;124(9):1473-80. doi: 10.1182/blood-2014-04-571091. Epub 2014 Jun 3.
9
Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation.对肝细胞腺瘤的基因组分析揭示了 FRK 激活突变的重现和恶性转化的机制。
Cancer Cell. 2014 Apr 14;25(4):428-41. doi: 10.1016/j.ccr.2014.03.005.
10
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.基因表达谱可明确外周 T 细胞淋巴瘤的生物学和预后亚群。
Blood. 2014 May 8;123(19):2915-23. doi: 10.1182/blood-2013-11-536359. Epub 2014 Mar 14.